Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denileukin diftitox

Drug Profile

Denileukin diftitox

Alternative Names: DAB389IL-2; DAB389 interleukin-2; E7272; E7777; Interleukin-2 diphtheria toxin fusion protein; Interleukin-2 fusion toxin; LY 335348; ONTAK

Latest Information Update: 18 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ajinomoto; Japanese Foundation for Cancer Research
  • Developer Eisai Co Ltd; TSD Japan
  • Class ADP ribose transferases; Antineoplastics; Bacterial toxins; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma
  • Phase II Malignant melanoma; Peripheral T-cell lymphoma
  • Discontinued Alopecia; Atopic dermatitis; HIV infections; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2016 Dr. Reddy's acquires the rights to develop and commercialise denileukin diftitox worldwide, excluding Asia and Japan
  • 01 Mar 2016 Phase-II clinical trials in Cutaneous T-cell lymphoma (Second-line therapy or greater) in Japan (IV) (NCT02676778)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top